Literature DB >> 26818654

Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes.

Kouichi Tamura1, Hiromichi Wakui1, Kengo Azushima1, Kazushi Uneda1, Satoshi Umemura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26818654     DOI： 10.1038/hr.2016.1

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  22 in total

1.  Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives.

Authors:  Motoko Ozawa; Kouichi Tamura; Yasuko Okano; Kouhei Matsushita; Mai Yanagi; Yuko Tsurumi-Ikeya; Jin Oshikawa; Tatsuo Hashimoto; Shinichiro Masuda; Hiromichi Wakui; Atsu-Ichiro Shigenaga; Kouichi Azuma; Tomoaki Ishigami; Yoshiyuki Toya; Toshiyuki Ishikawa; Satoshi Umemura
Journal:  Clin Exp Hypertens       Date:  2009-05       Impact factor: 1.749

2.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

3.  Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

Authors:  Ilkka Tikkanen; Kirsi Narko; Cordula Zeller; Alexandra Green; Afshin Salsali; Uli C Broedl; Hans J Woerle
Journal:  Diabetes Care       Date:  2014-09-30       Impact factor: 19.112

4.  Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Pieter A de Graeff; Gozewijn D Laverman; Tom Berl; Giuseppe Remuzzi; David Packham; Julia B Lewis; Hans-Henrik Parving; Hiddo J Lambers Heerspink
Journal:  Eur Heart J       Date:  2011-03-18       Impact factor: 29.983

Review 5.  The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy.

Authors:  Atsuhisa Sato
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

6.  Ambulatory blood pressure and heart rate in hypertensives with renal failure: comparison between diabetic nephropathy and non-diabetic glomerulopathy.

Authors:  Kouichi Tamura; Junji Yamauchi; Yuko Tsurumi-Ikeya; Masashi Sakai; Motoko Ozawa; Atsuichiro Shigenaga; Koichi Azuma; Yasuko Okano; Tomoaki Ishigami; Yoshiyuki Toya; Machiko Yabana; Yasuo Tokita; Toshimasa Ohnishi; Satoshi Umemura
Journal:  Clin Exp Hypertens       Date:  2008-01       Impact factor: 1.749

Review 7.  Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Authors:  Sunil Nair; John P H Wilding
Journal:  J Clin Endocrinol Metab       Date:  2009-11-05       Impact factor: 5.958

8.  Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Authors:  Vlado Perkovic; Hiddo Lambers Heerspink; John Chalmers; Mark Woodward; Min Jun; Qiang Li; Stephen MacMahon; Mark E Cooper; Pavel Hamet; Michel Marre; Carl Erik Mogensen; Neil Poulter; Giuseppe Mancia; Alan Cass; Anushka Patel; Sophia Zoungas
Journal:  Kidney Int       Date:  2013-01-09       Impact factor: 10.612

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112
View more
  5 in total

Review 1.  Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.

Authors:  André J Scheen
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 2.  Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Authors:  Asadur Rahman; Hirofumi Hitomi; Akira Nishiyama
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

3.  Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats.

Authors:  Tomoko Yoshikawa; Takuya Kishi; Keisuke Shinohara; Ko Takesue; Risa Shibata; Noriyuki Sonoda; Toyoshi Inoguchi; Kenji Sunagawa; Hiroyuki Tsutsui; Yoshitaka Hirooka
Journal:  Hypertens Res       Date:  2017-02-16       Impact factor: 3.872

Review 4.  An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.

Authors:  Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Luca Rinaldi; Anna Di Martino; Gaetana Albanese; Jessica Di Salvo; Raffaella Epifani; Raffaele Marfella; Giovanni Docimo; Miriam Lettieri; Celestino Sardu; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

Review 5.  SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives.

Authors:  Alexia Piperidou; Charalampos Loutradis; Pantelis Sarafidis
Journal:  J Hum Hypertens       Date:  2020-08-10       Impact factor: 3.012
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.